Table 2 Antibiotic exposures among the study population
Antibiotics | N (%) | Treatment days, median (IQR) |
|---|---|---|
Aminoglycosides | 65 (87%) | 5 (3, 10) |
 Amikacin | 36 (48%) |  |
 Gentamicin | 64 (85%) |  |
Carbapenems | 18 (24%) | 0 (0, 0) |
 Meropenem | 18 (24%) |  |
Cephalosporins | 27 (36%) | 0 (0, 3) |
 Cefazolin | 5 (7%) |  |
 Cefepime | 2 (3%) |  |
 Cefotaxime | 25 (33%) |  |
 Ceftazidime | 3 (4%) |  |
Glycopeptides | 6 (8%) | 0 (0, 0) |
 Vancomycin | 6 (8%) |  |
Macrolides | 2 (3%) | 0 (0, 0) |
 Azithromycin | 1 (1%) |  |
 Erythromycin | 1 (1%) |  |
Nitroimidazoles | 11 (15%) | 0 (0, 0) |
 Metronidazole | 11 (15%) |  |
Penicillins | 66 (88%) | 6 (3, 11) |
 Amoxicillin | 1 (1%) |  |
 Ampicillin | 7 (9%) |  |
 Ampicillin-sulbactam | 3 (4%) |  |
 Benzylpenicillin | 60 (80%) |  |
 Cloxacillin | 35 (47%) |  |